Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 90

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 90
---
 transactions. If these transactions are not ratified, our management must make all reasonable efforts to cancel or annul such transactions. Our management must update our Audit Committee on material changes to any approved or ratified related person transaction and provide an annual status report on all then-current related person transactions.

The following are certain transactions, arrangements and relationships with our directors, executive officers and stockholders owning 5% or more of our outstanding Common Stock since January 1, 2024.

#### 2023 Securities Purchase Agreement
On November 13, 2023, the Company entered into the a securities purchase agreement with (i) Timothy A. Springer, Ph.D., (ii) TAS, an affiliate of Dr. Springer, and (iii) Seven One Eight Three Four Irrevocable Trust, a trust associated with Murat Kalayoglu, M.D., Ph.D., in which the Company agreed to issue and sell an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25 million (the “2023 Private Placement”). We granted customary registration rights to investors in connection with the 2023 Private Placement. For further description of the 2023 Private Placement, see Note 11 to our consolidated audited financial statements included in our 2024 Annual Report. The 2023 Private Placement included a delayed settlement mechanism, and as a result, the below issuances and sales to related parties of the Company were made during the year ended December 31, 2024.

| Name                       |     | Shares of Series A Preferred Stock purchased |            |     | Total aggregate purchase price 
 (in thousands)                 |        |
|:---------------------------|:----|:---------------------------------------------|-----------:|:----|:-------------------------------|-------:|
| Timothy A. Springer, Ph.D. |     |                                              | 99,140.326 |     | $                              | 40,000 |

#### Exercise of Warrants
On March 26, 2024, TAS, an affiliate of Dr. Springer, exercised 65,681 warrants to purchase Common Stock, paid the per-share exercise price of $43.80 in cash for an aggregate exercise price of $2.9 million, and upon exercise received 65,681 shares of Common Stock and 1,970,443 contingent value rights.

#### 2024 Securities Purchase Agreement
On July 2, 2024, the Company entered into a securities purchase agreement for a private investment in public equity